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Abstract
This article highlights a recent study by Holst et al. in Nature
Genetics that finds estrogen receptor-alpha (ER-α) amplification in
early benign lesions and more advanced invasive carcinomas of the
breast, and discusses the potential implications to our present
understanding of the role of ER-α in breast tumorigenesis.
Introduction
A key discovery that sparked bench-to-bedside break-
throughs in the field of breast cancer was the recognition of
the hormone-dependence of many breast cancers.
Observations made by Cooper and Beatson correlated the
size of breast tumors with the phases of the menstrual cycle
and showed that ovariectomy caused tumor regression and
improved prognosis [1,2]. We now know that estrogen and
its receptor, estrogen receptor-α (ERα), underlie these
effects through the transcriptional regulation of genes
involved in cell proliferation and differentiation. Understanding
the mechanisms of estrogen and ERα action created the
foundation for the design of therapies that interfere with
estrogen signaling and block tumor growth. These include:
reduction of endogenous estrogens via aromatase inhibitors
(exemestane, anastrazole, letrozole) and/or ovariectomy; inter-
ference of ER-mediated transcriptional control via selective
ER modulators (tamoxifen); and degradation of the receptor
via selective ER downregulator compounds (fulvestrant).
These approaches are generally successful at prolonging
patient survival for those tumors expressing ERα and have
less toxic side effects than chemotherapy. For instance, it
was estimated that tamoxifen has saved the lives of 400,000
women since its introduction in the 1970s [3].
Has this achievement tempted us into complacency with
regard to the extent of our understanding of ERα’s role in the
pathogenesis of breast cancer? Given the large, on-going
research effort and number of publications devoted to
estrogen in breast cancer (26,303 articles entered into
PubMed as of June 2007), some individuals would say no.
Yet, a recent report by Holst et al. [4] in Nature Genetics was
the first to investigate whether a common mechanism of
oncogene activation, gene amplification, occurred at the ERα
gene locus during tumor progression. Their work is an
important scientific contribution that expands upon prior
studies demonstrating ESR1 gene amplification in breast
cancer cell lines and in some advanced tumors [5-7].
Causes of ERα α overexpression in breast
cancer
The pattern of ERα expression in normal breast tissue
compared with precancerous and cancerous lesions is
strikingly different. In normal breast tissue, ERα expression is
restricted to a small proportion of non-proliferating luminal
epithelial cells, typically at low to intermediate levels [8,9].
However, in more than half of premalignant lesions and
carcinomas, this dissociation breaks down and the receptor
is detected in proliferating cells, generally at higher levels [8].
Additionally, there is a striking increase in the intracellular
amount of ERα protein [10]. A significant unknown in the field
of breast cancer is what drives the change in ERα expression
and distribution in breast lesions. Holst et al. [4] used
fluorescence in situ hybridization (FISH) to probe a tissue
microarray containing 2,222 invasive breast cancers and 295
normal, pre-malignant, and pre-invasive samples and found
ESR1 gene amplification in 358 samples (21%) of the 1,739
invasive breast carcinomas with analyzable FISH data.
Virtually all (99%) cases with amplification exhibited corres-
pondingly high ERα protein levels as measured by immuno-
histochemistry. Characterization of the ESR1 amplicon at
6q25.1 by PCR-based methods found that it was relatively
small and did not extend into any other genes. Furthermore,
ESR2, which encodes a second ER, ERß, was not amplified.
Amplification of other known oncogenes (HER2/neu, MDM2,
MYC,  EGFR) was detected in invasive cancer samples,
although these were found to be independent of ESR1
amplification. Interestingly, ESR1 amplification was observed
in proliferative benign breast lesions (36.4% of papillomas
and 8.3% of usual ductal hyperplasia) and carcinomas in situ
(35% ductal and 33% lobular) in addition to more advanced
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tumors [4]. While these studies require independent
validation, the data provide evidence that amplification of ERα
appears in early lesions and may contribute, in part, to the
appearance of high levels of ERα in breast tumorigenesis.
Gene amplification alone, however, cannot explain all cases
involving high ERα protein levels. Only 54% of cancers with
high ERα expression also had gene amplification [4]. The
remaining 46% showed high ERα expression without gene
amplification [4]. This suggests that other mechanisms contri-
bute to high ERα protein levels, such as altered regulation of
ESR1 transcription, mRNA stability, or ERα protein turnover.
For example, recent studies have demonstrated that disrup-
tion of caveolin-1 and micro-ribonucleic acid 206 can increase
ERα levels [11,12]. How such upstream factors regulate the
ERα gene and protein is not well understood and needs
further attention.
Role of misregulated ERα α expression in
breast tumorigenesis
A significant point raised by the finding of ESR1 amplification
in early lesions is whether high levels of ERα expression are a
cause or consequence of malignant transformation. Studies
of HER2/neu provide a clear example where overexpression
of an amplified gene product is oncogenic [13]. Could this
also be the case for ERα?  ESR1 gene amplification was
identified in several benign proliferative breast lesions, which
increase a patient’s risk of cancer [14]. Studies have shown
that high levels of ERα are present in benign epithelium of
women with breast cancer compared to controls and there is
an inability to downregulate the receptor in response to
estrogen in these cases, supporting a potential role for ERα
overexpression in breast cancer risk [15,16]. Transgenic
mouse models also indicate that overexpression of ERα is
sufficient for the development of ductal hyperplasia, lobular
hyperplasia, and ductal carcinoma in situ [17].
How high ERα levels might contribute to tumorigenesis is
less understood. The simplest explanation is that the
presence of additional receptors supports a more robust
response to estrogen. An alternative and intriguing possibility
comes from analogy of studies conducted on ErbB2/Her2-
neu. Proteomic analysis of ErbB2 protein interactions
showed that elevated concentrations of ErbB2 lead to
promiscuous interactions and promote activation of distinct
signaling pathways [18]. In this model, overexpression of the
oncoprotein, resulting from amplification or other processes,
could lead to an expansion of its regulatory role by permitting
protein interactions that activate non-canonical signaling
pathways. Similar findings have been reported for ERα in a
breast cancer cell model system of ERα overexpression in
which the mechanism of transactivation and target gene
regulation differ when ERα protein levels are elevated
[19,20]. These studies of ErbB2 and ERα overexpression
raise the interesting scenario that perhaps ERα in normal
breast epithelium is maintained at restrictive levels that are
necessary to promote differentiation. When the ERα protein
concentration increases during tumorigenesis, promiscuous
interactions with coregulatory proteins or DNA could lead to
the activation of proliferative signaling pathways, which, at
normal levels of expression, would be too weak to occur. This
scenario would predict that amplification or overexpression of
ERα would be causally related to the high proliferative
capacity of ER+ cells. This possibility remains to be tested.
Clinical implications
Classification of tumors into subtypes helps predict thera-
peutic responses and patient survival. Categorizing breast
tumors as either ERα positive or negative by immuno-
histochemistry has proved clinically useful in determining
which patients would benefit from endocrine therapy. More
recently, microarray analysis has further refined the groupings
of breast tumors on the basis of distinct gene expression
profiles: basal-like, HER2+/ER-, normal breast-like, luminal A,
and luminal B [21]. The latter has clearly shown that the ER
positive cohort is not a single group of patients. Both luminal
A and B subtypes are ER+; however, patients with luminal B
tumors have poorer outcomes. The ER+ cohort can also be
subdivided into IE and IIE subtypes. The group IIE tumors are
similar to subtype B and express more proliferative genes
[22]. The same proliferative gene signature was shown by Dai
et al. [23] to be a marker of poor outcome in patients with
tumors expressing high levels of ERα for their age. Although
it is currently standard practice to offer hormonal therapy to
all patients categorized as ER+, these and other studies
demonstrate marked heterogeneity within this group in terms
of gene expression profiles and patient survival.
Holst et al. [4] analyzed the clinical utility of classifying tumors
based on ESR1 amplification. Phenotypes associated with
ESR1 amplification included low tumor grade and lack of
lymph node metastases, both positive prognostic indicators.
Furthermore, tumors with ESR1 amplification were associa-
ted with longer survival in patients treated with adjuvant
tamoxifen compared with non-ESR1 amplified and ER-nega-
tive tumors. However, there was no statistically significant
difference in survival for patients with cancers having ESR1
amplification compared to patients with non-ESR1 amplified
cancers containing the highest level of ERα protein
(P = 0.09). Thus, the classification of tumors based on ESR1
amplification does not yield more clinical information than
does the current method of tumor characterization based on
ERα protein levels.
While all breast cancers are analyzed for the expression of
ERα, steroid receptor status is not routinely measured for
benign breast lesions. Depending on the level of suspicion,
biopsy-proven benign lesions can either be surgically excised
or followed with imaging. One histological group whose
management is currently under debate comprises benign
papillary lesions, which includes papilloma [24]. Holst et al.
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benign papilloma samples. Furthermore, elevated ERα
protein levels have been demonstrated for papillomas and are
associated with increased proliferation [25]. Measurement of
ESR1 gene amplification or ERα protein levels for papillary
lesions may be potentially useful since the presence of
amplification or overexpression would argue in favor of
surgical excision instead of follow-up imaging.
Conclusion
Over 100 years have passed since the discovery of the
importance of estrogen and, later, ERα to the growth of
breast tumors. Since that time, tremendous advances have
been made in our understanding of the molecular mecha-
nisms of ERα activity and in the application of this knowledge
to the development of therapies for the prevention and
treatment of breast cancer. The recent discovery of ERα
amplification in early breast lesions by Holst et al. is an
important reminder that, despite our perception that we
understand how ERα contributes to pathogenesis, there are
still major questions that remain unanswered and break-
throughs to be made. Major clinical dilemmas still revolve
around how better to predict response to hormonal therapy
and how to fight endocrine resistance. Thus, in 2007, the
question, “How does ER contribute to breast cancer?”
remains one worth asking.
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